Master of Science
Epidemiology and Biostatistics
Dr. Daniel Hackam
We conducted a systematic review and meta-analysis to assess the association of MTX with cardiovascular morbidity, cardiovascular mortality and all-cause mortality in patients with autoimmune disease. Our primary outcome was incident cardiovascular events. After screening 13,479 citations, we identified a total of 30 eligible studies. We synthesized adjusted risk estimates using a random effects model. MTX was significantly associated with a 25% reduction in cardiovascular events (pooled RR: 0.75, 95% CI: 0.65, 0.86, I2: 11%), a 55% reduction in cardiovascular mortality (0.45, 95% CI: 0.26, 0.80, I2: 33%) and a 40% reduction in all-cause mortality (0.60, 95% CI: 0.48, 0.76, I2: 45%). Low-dose MTX was associated with a stronger effect size for reducing cardiovascular events compared to high-dose MTX (0.61, 95% CI: 0.51, 0.74 versus 0.88, 95% CI: 0.78, 0.99). We concluded a significant associative reduction in cardiovascular events with the use of low-dose MTX in patients with autoimmune disease.
Shah, Alpesh, "Methotrexate and cardiovascular events" (2015). Electronic Thesis and Dissertation Repository. 2732.
Cardiology Commons, Cardiovascular Diseases Commons, Dermatology Commons, Immune System Diseases Commons, Musculoskeletal Diseases Commons, Rheumatology Commons, Skin and Connective Tissue Diseases Commons, Therapeutics Commons